HASBROUCK HEIGHTS, N.J., September 18 /CNW/ - Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) is pleased to announce the new publication of an
independent study reporting positive data on the accuracy and usefulness of
the Company's Saliva NicAlert(TM) test for tobacco exposure in a family
practice setting. Saliva NicAlert(TM) results using saliva samples tested
on-site closely matched those obtained by much more expensive and complex
testing technology using urine samples sent off-site to an independent
reference laboratory. Importantly, Saliva NicAlert(TM) was able to correctly
identify smokers who reported being nonsmokers but were ascertained to
actually be smokers based on the reference laboratory liquid
chromatography/mass spectroscopy results.
The paper, "Validation of Self-Reported Smoking Status Using Saliva
Cotinine: A Rapid Semiquantitative Dipstick Method," (Cancer Epidemiol
Biomarkers Prev. Sep 2007;16:1858-62) is in the current issue of Cancer
Epidemiology Biomarkers & Prevention, published by the American Association
for Cancer Research (AACR) and is co-authored by principal investigators, Dr.
Norman J. Montalto and Dr. Wayne O. Wells, both physicians with long-standing
interest and expertise in the field of tobacco use and dependency. The studies
involved 172 patients aged 6 to 80 at family practice medical clinics
supervised by Dr. Montalto and Dr. Wells.
"It is widely believed that physicians should routinely verify the
smoking status of every patient. There are many situations where an accurate
and convenient on the spot test is particularly important, such as
preoperative assessment, allergy and pregnancy clinics or when prescribing
oral contraceptives. Saliva is easy to obtain and having immediate results
gives the clinician a powerful tool to counsel patients", said Brian Doyle,
Senior Manager for Saliva NicAlert(TM).
NicAlert(TM) Saliva, the Company's saliva-based version of its
NicAlert(TM) product, has achieved certification with the CE Mark, permitting
its sale in the European Union. The new product uses easily obtainable saliva
samples to provide an easy-to-use, on-site visual read-out of an individual's
level of tobacco use or exposure. The product requires no instruments or
special training. The urine-based version of NicAlert(TM) received clearance
from the U.S. Food and Drug Administration and achieved certification with the
Cigarette smoking is the single most preventable cause of premature death
in the United States. Each year, over 400,000 people die as a result of
tobacco use and exposure in the U.S. alone. Experts in the field have long
advocated that physicians should treat the routine assessment of smoking and
other tobacco product use of patients in the clinic as an important "vital
sign" for health risk reduction strategies and appropriate disease management.
More information about Nymox is available at www.nymox.com, email:
email@example.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of 1995
that involve a number of risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and the actual results and
future events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug and diagnostic
products involve substantial risks and uncertainties and actual results may
differ materially from expectations. Promising early results do not ensure
that later stage or larger scale clinical trials will be successful or will
proceed as expected. Such factors are detailed from time to time in Nymox's
filings with the United States Securities and Exchange Commission and other
For further information:
For further information: Nymox Pharmaceutical Corporation Roy Wolvin,